Cognitive function and quality of life in interferon therapy for melanoma

Clinical Nursing Research

Volumn 9, Issue 3, 2000, Pages 352-363

  Bender, Catherine M ^a   Yasko, Joyce M ^a   Kirkwood, John M ^a   Ryan, Christopher ^a   Dunbar Jacob, Jacqueline ^a   Zullo, Thomas ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

ARTICLE; CLINICAL NURSING RESEARCH; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MELANOMA; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL NURSING RESEARCH; COGNITION; HUMANS; INTERFERON ALFA-2B; MELANOMA; QUALITY OF LIFE; SKIN NEOPLASMS;

EID: 0034252875     PISSN: 10547738     EISSN: None     Source Type: Journal    
DOI: 10.1177/10547730022158537     Document Type: Article

References (9)

1. Adams, F., Quesada, J. R., & Gutterman, J. U. (1984). Neuropsychiatrie manifestations of human leukocyte interferon therapy in patients with cancer. Journal of the American Medical Association, 252(7), 938-941.
2. Boone, D.E. (1992). Reliability of the WAIS-R with psychiatric inpatients. Journal of Clinical Psychiatry, 48(11). 72-76.
3. Bornstein, R. A. (1987). Normative data on selected neuropsychological data from a nonclinlcal sample. Perceptual and Motor Skills, 41, 651-659.
4. Cella, D. F., Tulsky, D. S., Gray, G., Sarafin, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., Brannon, J., Eckberg, K., Lloyd, S., Purl, S., Blendowski, C., Goodman, M., et al. (1993). The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570-579.
5. Denicoff, K. D., Rubinow, D. R., Papa, M. Z., Simpson. C., Seipp, C. A., Lotze, M. T., Chang, A. E., Rosenstein, D., & Rosenberg, S. A. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphoklne activated killer cells. Annals of Internal Medicine, 107, 293-300.
6. Ferrans, C. E. (1990). Development of a quality of life index for patients with cancer. Oncology Nursing Forum, 17(Suppl. 3), 15-21.
7. Kirkwood, J. M. (1991). Intergrouppost-operative adjuvant alpha 2 interferon in resected high risk primary and regionally metastatic melanoma. Pittsburgh, PA: Eastern Cooperative Oncology Group.
8. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996). Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology, 14(1), 7-17.
9. Lafayette Clinical Repeatable Neuropsychological Test Battery. (1989). Sagamore, Indiana: Lafayette Clinical Instrument Company.